Literature DB >> 19443172

Microarray analysis of microRNA expression in renal clear cell carcinoma.

Y Huang1, Y Dai, J Yang, T Chen, Y Yin, M Tang, C Hu, L Zhang.   

Abstract

AIM: To explore the microRNA (miRNA) expression in renal clear cell carcinoma (RCCC).
METHODS: We compared the miRNA expression profiles in 11 pairs of RCCC and adjacent nontumorous tissue (NT) from 11 RCCC patients, using a mammalian miRNA microarray containing whole human mature and precursor miRNA sequences. To verify microarray results, Northern blotting was carried out on 5 randomly selected miRNAs.
RESULTS: Totally 81 miRNAs were identified valid expression in RCCC samples, 48 of which specifically detected in RCCC samples, 17 of which detected downregulated in RCCC compared to NT sample, 2 upregulated and 14 without significant difference. MiRNAs in RCCC tissues exhibit an overall higher expression level than NT tissue. The chip results were confirmed by northern blot analysis.
CONCLUSION: Our study may help to clarify the molecular mechanisms involved in the pathogenesis of RCCC, and miRNAs potentially serve as a novel diagnostic biomarker of RCCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443172     DOI: 10.1016/j.ejso.2009.04.010

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  40 in total

1.  Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.

Authors:  Emmanuel I Papadopoulos; George M Yousef; Andreas Scorilas
Journal:  Tumour Biol       Date:  2015-04-02

Review 2.  microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles.

Authors:  Kirti Bhatt; Qing-Sheng Mi; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-12

3.  Comparison of exosomal microRNAs secreted by 786-O clear cell renal carcinoma cells and HK-2 proximal tubule-derived cells in culture identifies microRNA-205 as a potential biomarker of clear cell renal carcinoma.

Authors:  Victor C Crentsil; Hui Liu; Donald F Sellitti
Journal:  Oncol Lett       Date:  2018-05-21       Impact factor: 2.967

Review 4.  Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors.

Authors:  Annika Schaefer; Carsten Stephan; Jonas Busch; George M Yousef; Klaus Jung
Journal:  Nat Rev Urol       Date:  2010-04-06       Impact factor: 14.432

Review 5.  The epigenetic landscape of renal cancer.

Authors:  Mark R Morris; Farida Latif
Journal:  Nat Rev Nephrol       Date:  2016-11-28       Impact factor: 28.314

Review 6.  Basic research in kidney cancer.

Authors:  Egbert Oosterwijk; W Kimryn Rathmell; Kerstin Junker; A Rose Brannon; Frédéric Pouliot; David S Finley; Peter F A Mulders; Ziya Kirkali; Hirotsugo Uemura; Arie Belldegrun
Journal:  Eur Urol       Date:  2011-07-05       Impact factor: 20.096

7.  Tumor suppressive miR-509-5p contributes to cell migration, proliferation and antiapoptosis in renal cell carcinoma.

Authors:  W-B Zhang; Z-Q Pan; Q-S Yang; X-M Zheng
Journal:  Ir J Med Sci       Date:  2013-04-26       Impact factor: 1.568

8.  Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma.

Authors:  Huiqing Liu; Angela R Brannon; Anupama R Reddy; Gabriela Alexe; Michael W Seiler; Alexandra Arreola; Jay H Oza; Ming Yao; David Juan; Louis S Liou; Shridar Ganesan; Arnold J Levine; W K Rathmell; Gyan V Bhanot
Journal:  BMC Syst Biol       Date:  2010-04-27

9.  MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients.

Authors:  Kai Doberstein; Nico Steinmeyer; Ann-Kathrin Hartmetz; Wolfgang Eberhardt; Michel Mittelbronn; Patrick N Harter; Eva Juengel; Roman Blaheta; Josef Pfeilschifter; Paul Gutwein
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

10.  MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma.

Authors:  Martina Redova; Alexandr Poprach; Andrej Besse; Robert Iliev; Jana Nekvindova; Radek Lakomy; Lenka Radova; Marek Svoboda; Jan Dolezel; Rostislav Vyzula; Ondrej Slaby
Journal:  Tumour Biol       Date:  2012-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.